Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12608000013369
Ethics application status
Not yet submitted
Date submitted
27/12/2007
Date registered
10/01/2008
Date last updated
10/01/2008
Type of registration
Prospectively registered
Titles & IDs
Public title
Immune regulation and timing of chemotherapy in advanced/recurrent ovarian cancer to evaluate tumour response
Query!
Scientific title
Immune regulation and timing of chemotherapy in advanced/recurrent ovarian cancer to evaluate tumour response
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Recurrent Ovarian Cancer
2693
0
Query!
Condition category
Condition code
Cancer
2811
2811
0
0
Query!
Ovarian and primary peritoneal
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Synchronised chemotherapy using cyclophosphamide 100 mg orally for 3 days each 2 week cycle for at least 3 cycles
Query!
Intervention code [1]
2400
0
Treatment: Other
Query!
Intervention code [2]
2429
0
Treatment: Drugs
Query!
Comparator / control treatment
None
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
3683
0
Tumour response (Recist criteria)
Query!
Assessment method [1]
3683
0
Query!
Timepoint [1]
3683
0
18 months
Query!
Primary outcome [2]
3697
0
CA125 response as measured in peripheral blood.Gynaecological Cancer Intergroup criteria
Query!
Assessment method [2]
3697
0
Query!
Timepoint [2]
3697
0
2 weeks following last of 3 treatment cycles
Query!
Secondary outcome [1]
6188
0
Survival
Query!
Assessment method [1]
6188
0
Query!
Timepoint [1]
6188
0
18 months
Query!
Secondary outcome [2]
6242
0
Progression free survival
Query!
Assessment method [2]
6242
0
Query!
Timepoint [2]
6242
0
At 6 months following trial completion
Query!
Eligibility
Key inclusion criteria
Rising CA125 (Rustin)
2 previous lines of chemotherapy
Query!
Minimum age
21
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Impending bowel obstruction
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
1/03/2008
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
37
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Funding & Sponsors
Funding source category [1]
2945
0
Self funded/Unfunded
Query!
Name [1]
2945
0
Query!
Address [1]
2945
0
Query!
Country [1]
2945
0
Query!
Funding source category [2]
2953
0
Hospital
Query!
Name [2]
2953
0
Royal Women's Hospital
Query!
Address [2]
2953
0
132 Grattan St Carlton 3053
Query!
Country [2]
2953
0
Australia
Query!
Primary sponsor type
Hospital
Query!
Name
Royal Women's Hospital
Query!
Address
132 Grattan St
Carlton
Query!
Country
Australia
Query!
Secondary sponsor category [1]
2634
0
None
Query!
Name [1]
2634
0
Query!
Address [1]
2634
0
Query!
Country [1]
2634
0
Query!
Ethics approval
Ethics application status
Not yet submitted
Query!
Ethics committee name [1]
4887
0
Query!
Ethics committee address [1]
4887
0
Query!
Ethics committee country [1]
4887
0
Query!
Date submitted for ethics approval [1]
4887
0
09/01/2008
Query!
Approval date [1]
4887
0
Query!
Ethics approval number [1]
4887
0
Query!
Summary
Brief summary
We have shown that the immune system regulates itself on an approximately 2 week basis.By killing the inhibitory immune cells that prevent immune attack on the tumour using low dose oral chemotherapy it is hoped that tumour cells will die and responses achieved
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
28262
0
Query!
Address
28262
0
Query!
Country
28262
0
Query!
Phone
28262
0
Query!
Fax
28262
0
Query!
Email
28262
0
Query!
Contact person for public queries
Name
11419
0
Prof Michael Quinn
Query!
Address
11419
0
285 Cardigan St
Carlton
Query!
Country
11419
0
Australia
Query!
Phone
11419
0
0392215188
Query!
Fax
11419
0
Query!
Email
11419
0
[email protected]
Query!
Contact person for scientific queries
Name
2347
0
Prof Michael Quinn
Query!
Address
2347
0
285 Cardigan St
Carlton
Query!
Country
2347
0
Australia
Query!
Phone
2347
0
0392215188
Query!
Fax
2347
0
Query!
Email
2347
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF